PMC

(A) Schedule of treatments administered for three lymphodepleting cell transfer regimens. (B) Kaplan-Meier plot showing the duration of survival of patients treated on each lymphodepleting cell transfer protocol. Vertical tick marks indicate patients who are still alive and on study. Cy, cyclophosphamide; Flu, fludarabine; TBI, total-body irradiation; CD34⁺, hematopoietic stem cells; TIL, tumor-infiltrating lymphocytes; IL-, interleukin.

Transient depression of hematopoietic cell counts resulting from lymphodepletion is rapidly reversed in patients on all three clinical protocols. Mean absolute counts were calculated based on daily CBCs for all patients who received lymphodepletion and tumor-infiltrating lymphocytes (TIL) therapy as their first lymphodepleting cell therapy. (A) Absolute neutrophil counts, (B) absolute lymphocyte counts, and (C) platelet counts. NMA, nonmyeloablative; TBI, total-body irradiation.

Adoptive cell therapy after lymphodepletion. (A) Telomere length of infused tumor-infiltrating lymphocytes (TIL) correlates with clinical response. Flow-fluorescent in situ hybridization analysis was used to quantify the mean telomere length of infused TIL for patients on all three protocols. (B) Lymphodepleting conditioning markedly increases the levels of circulating homeostatic cytokines, interleukin (IL)-7 and IL-15. Serum samples were evaluated before therapy (Pre) and immediately before TIL administration (day 0). NMA, nonmyeloablative; TBI, total-body irradiation.